Geniculate Artery Embolization for Treatment of Osteoarthritis

  • End date
    Jun 18, 2023
  • participants needed
  • sponsor
    NYU Langone Health
Updated on 18 February 2021


Single-arm, single-center, no sham or placebo, prospective pilot trial designed to evaluate the feasibility and safety of transcatheter arterial embolization in patients with mild to moderate radiographic knee OA. Eligible participants will receive geniculate artery embolization using Embozene Color-Advanced Microspheres. Patients will be followed up for a total of 12 months.


The current study seeks to determine whether transcatheter arterial embolization of abnormal neovasculature arising from the genicular arterial branches is safe and effective in the treatment of mild-to-moderate knee OA.

Condition Arthritis, Osteoarthritis, Arthritis and Arthritic Pain, Arthritis and Arthritic Pain (Pediatric), degenerative arthritis
Treatment Transcatheter arterial embolization, Embozene™ Microspheres
Clinical Study IdentifierNCT04379700
SponsorNYU Langone Health
Last Modified on18 February 2021


Yes No Not Sure

Inclusion Criteria

-75 years of age of any gender
Kellgren-Lawrence Grade 2, or 3 knee OA on most recent knee radiograph obtained within 6 months of screening visit and
Knee pain resistant to conservative treatment for at least 3 months
Moderate to severe knee pain: pain VAS 40 mm with 0 representing 'no pain' and 100 'the worst pain imaginable
Willing, able, and mentally competent to provide informed consent

Exclusion Criteria

< 30 or > 75 years of age or
Active systemic or local knee infection or
Active malignancy or
Life expectancy less than 12 months or
Prior ipsilateral knee surgery excluding arthroscopic surgery more than 6 months ago or
Ipsilateral knee intra-articular injection in the last 3 months or
Kellgren-Lawrence Grade 1 or 4 knee OA on knee radiograph or
Rheumatoid arthritis, spondyloarthropathies, crystal disease, gout, pseudogout, or lupus
Pregnant during the study period or
Renal dysfunction as defined by serum creatinine >1.6 dl/mg or eGFR <60 obtained within 30 days of procedure or
Body weight greater than 200 Kg or
Uncorrectable coagulopathy (platelet count < 50,000, international normalized ratio >1.5 within 30 days of procedure; or
Known history of contrast allergy resulting in anaphylaxis or
Known significant arterial atherosclerosis that would limit selective angiography
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note